C

Cibus Inc
NASDAQ:CBUS

Watchlist Manager
Cibus Inc
NASDAQ:CBUS
Watchlist
Price: 1.45 USD -8.23% Market Closed
Market Cap: 49.9m USD

Relative Value

The Relative Value of one CBUS stock under the Base Case scenario is 19.32 USD. Compared to the current market price of 1.45 USD, Cibus Inc is Undervalued by 92%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CBUS Relative Value
Base Case
19.32 USD
Undervaluation 92%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
33
Median 3Y
52.5
Median 5Y
14.7
Industry
7.2
Forward
8.4
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-1.5
Industry
23.2
Forward
-0.5
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-3.4
Industry
19.3
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-3.2
Industry
22.5
vs History
82
vs Industry
66
Median 3Y
0.9
Median 5Y
1.4
Industry
2.7
vs History
66
vs Industry
34
Median 3Y
42.6
Median 5Y
13.2
Industry
7.5
Forward
4.2
vs History
vs Industry
1
Median 3Y
0
Median 5Y
-29.1
Industry
9.4
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.9
Industry
4.6
Forward
-0.3
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-1.7
Industry
4.5
Forward
-0.3
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-3.2
Industry
4.9
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-3
Industry
3.7
vs History
87
vs Industry
69
Median 3Y
0.3
Median 5Y
0.7
Industry
4.9

Multiples Across Competitors

CBUS Competitors Multiples
Cibus Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cibus Inc
NASDAQ:CBUS
47.4m USD 10 -0.2 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 536 021.3 -164 144.6 -199 323.9 -197 049.4
US
Abbvie Inc
NYSE:ABBV
327.6B USD 5.7 78.8 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
156B USD 4.6 26.3 14.2 23.4
US
Gilead Sciences Inc
NASDAQ:GILD
134.5B USD 4.7 22.5 9.8 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 10.2 -114.9 24.4 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 039.9 -520.5 -566.8 -551.7
AU
CSL Ltd
ASX:CSL
116B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.1B USD 3.9 12.2 10.8 12.2
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60.3 -64.9 -58.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.2B USD 17.1 -149.2 -668 -334.8
P/S Multiple
Revenue Growth P/S to Growth
US
C
Cibus Inc
NASDAQ:CBUS
Average P/S: 3 139 831.1
10
178%
0.1
FR
Pharnext SCA
OTC:PNEXF
34 536 021.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 039.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.9
4%
1
US
S
Seagen Inc
F:SGT
19.6
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
US
C
Cibus Inc
NASDAQ:CBUS
Average P/E: 33.4
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 144.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.8
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.5 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -149.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Cibus Inc
NASDAQ:CBUS
Average EV/EBITDA: 15.2
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 323.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -668 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Cibus Inc
NASDAQ:CBUS
Average EV/EBIT: 19.7
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 049.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -551.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -334.8 N/A N/A